SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a 'free and fair' meme coin on the Bitcoin blockchain, with the community emphasizing its decentralized nature and organic growth. Discussions revolve around accumulating during dips and the potential for 'DOG-TOBER', while some debate its relationship with $CBLO. The community continues to highlight its strong fundamentals and unique position within the meme coin landscape.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as reports suggest potential investment or partnership talks with Apple and TSMC, fueling optimism for the company's AI comeback bid. The community is highly engaged, viewing this as a pivotal moment, while some analysts debate the potential benefits for all parties involved. With the U.S. government's backing and strategic moves underway, investors are closely watching Intel's evolving position in the semiconductor landscape.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as the community discusses its potential, drawing comparisons to previous meme coin success stories like $PEPE. Many users are highlighting its accessibility and ease of purchase through the Phantom Wallet on the Solana network.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQQF is trending due to anticipation surrounding its upcoming Nasdaq uplisting, with the community actively discussing potential price movements and long-term prospects within the quantum computing sector. However, some investors are expressing concerns about a potential share offering, drawing comparisons to a similar situation with DEFT, another company associated with the same CEO. Discussions also revolve around the company's technology, its competitive positioning, and potential catalysts for growth.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending due to a recently announced $1.1B convertible notes offering and a $3B AI hosting agreement with Fluidstack, backed by Google. While the offering initially sparked concerns about dilution, the community is weighing this against the potential for growth and expansion into HPC, with some seeing it as a strategic move. Bullish sentiment highlights Google's involvement and long-term prospects in the AI data center space.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending as community members discuss a potential partnership between PSTV and UNH, with some suggesting Warren Buffet's involvement could boost PSTV. Additionally, rising premiums across insurance providers starting in 2026 may positively impact insurance stocks like UNH, especially with a potentially hot economy.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to a quantum computing breakthrough with HSBC, showing a 34% improvement in bond trading, sparking excitement about real-world applications of its Heron quantum processor. The community is also highlighting IBM's expanding AI business and undervalued status, seeing the company as a leader in quantum computing, AI consulting, and hybrid cloud solutions. Despite some bearish sentiment, many view IBM as a strong buy with potential for significant growth.

Amplify Energy Corp. is an independent oil and natural gas company, which engages in the acquisition, development, exploration, and production of oil and natural gas properties. It focuses on operations in Oklahoma, the Rockies, offshore Southern California, East Texas and North Louisiana, and Eagle Ford. The company was founded in 2011 and is headquartered in Houston, TX.

Amplify Energy Corp.

AMPY is trending due to high trading volume and community speculation around potential short squeezes and target prices, despite mixed opinions on the company's value and future performance. Some traders are encouraged by insider buying and improving financials, while others remain skeptical, pointing to past issues and lack of clear news driving the surge. The stock's movement is also influenced by broader trends in the oil and gas sector and fluctuating energy prices.

Almonty Industries, Inc. engages in mining, processing and shipment of tungsten concentrates. Its projects include Los Santos, Valtreixal, Almonty Korea Tungsten, Almonty Korea Moly, and Panasquiera. The company was founded on September 28, 2009 and is headquartered in Toronto, Canada.

Almonty Industries Inc

Almonty Industries ($ALM) is trending as investors discuss its potential role in securing a non-Chinese tungsten supply for the U.S., especially with the U.S. government's focus on critical minerals and recent government connections added to Almonty's board. Community members are closely watching for news on mine production commencement, expecting significant stock movement upon its announcement, and some analysts are pointing to the company's undervaluation and raising price targets.

N2OFF, Inc. is a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech. It delivers integrated solutions for sustainable energy, greenhouse gas emissions reduction and safety, quality solutions for the agri- tech market. Its products include SpuDefender and FreshProtect. The SpuDefender is designed to control the post-harvest potato sprout. The FreshProtect is designed to control spoilage-creating microorganisms on post-harvest citrus fruit. The firm operates through the following segments: Pathogen prevention and prolong shelf life and N2O emissions Global warming solutions. N2OFF was founded by Nimrod Ben-Yehuda on April 1, 2009 and is headquartered in Neve Yarak, Israel.

N2OFF Inc.

N2OFF ($NITO) is trending due to shareholder excitement around a merger with a drug discovery company, though some express skepticism and call it a pump and dump. Community members are actively debating the potential for pre-market pops and dilution, with some pointing to a history of similar patterns in Israeli stocks. Traders are also weighing the merger news against concerns about potential dilution and the stock's volatile history, contributing to the ongoing conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why JAZZ Stock Is an Unconventional Cannabis Investment

Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Jazz Pharmaceuticals experienced increased retail chatter on Wednesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Modeyso (dordaviprone)&nbsp;for the treatment of a specific form of brain tumor.The drug is approved to treat adult and pediatric patients aged one year and older with diffuse midline glioma carrying an H3 K27M mutation, following progression after prior therapy. Continued approval may depend on confirmatory results from the Phase 3 ACTION trial.Modeyso is the first FDA-approved therapy for this rare and aggressive brain tumor, which affects an estimated 2,000 people in the U.S. annually, many of them children and young adults, according to the company.The oral, once-weekly capsule is expected to be commercially available in the coming weeks. The FDA based its decision on data from 50 patients enrolled across five open-label studies. About 1 in 5 patients responded to treatment, with responses lasting a median of just over 10 months.&nbsp;Among those who responded, nearly three-quarters saw benefits for at least six months, and more than a quarter maintained their response for at least a year.Patrick Wen of Dana-Farber Cancer Institute called the approval a “major turning point in neuro-oncology,” noting that Modeyso introduces a new treatment option for a population with limited choices.&nbsp;About a third of glioma patients in the trial experienced serious side effects on Modeyso, including hydrocephalus, seizures, vomiting, and muscle weakness. Fatigue, nausea, and headaches were the most common complaints.Separately, Truist Securities reduced its price target on Jazz Pharmaceuticals to $200 from $230, citing slower momentum in Epidiolex and cancer therapies such as Rylaze and Zepzelca.&nbsp;In the second quarter, Rylaze revenue dropped 7% to $100.7 million, and Zepzelca sales slipped 8% to $74.5 million. Epidiolex posted modest 2% growth to $251.7 million.&nbsp;Truist noted that the company’s total revenue was propped up by strong momentum in the oxybate franchise, where the lead drug, Xywav, rose 13% to $415.3 million. However, it flagged potential headwinds from two upcoming non-oxybate narcolepsy treatments nearing FDA review.On Stocktwits, retail sentiment for Jazz Pharmaceuticals was ‘extremely bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/JAZZ">Jazz Pharmaceuticals’ stock</a> has declined 14.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jazz Pharmaceuticals (JAZZ) experienced increased retail chatter on Wednesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Modeyso  (Photo credit: Getty Images)

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor

The approval was based on pooled data from 50 patients in five open-label trials, showing an overall response rate of 22%, with a median response duration of 10.3 months.

Equity

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.

Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

JAZZ
Jazz Pharmaceuticals plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest JAZZ News

JAZZ Jazz Pharmaceuticals plc